ReviewVeterinary sciences2019
A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma.
Review in Veterinary sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.The veterinary quarterly · 2025Article
- Evaluation of Cytokine Profile in Canine Malignant Oral Melanoma.Veterinary sciences · 2025Article
- Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide-Tethered IL-12 in Dogs with Advanced Malignant Melanoma.Molecular cancer therapeutics · 2025Article
- Article
- Article
- Establishment of Canine Oral Mucosal Melanoma Cell Lines and Their Xenogeneic Animal Models.Cells · 2024Article
- Risk stratification scheme based on the TNM staging system for dogs with oral malignant melanoma centered on clinicopathologic presentation.Frontiers in veterinary science · 2024Article
- Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors.Animals : an open access journal from MDPI · 2023Article
- Article
- Single institution study of the immune landscape for canine oral melanoma based on transcriptome analysis of the primary tumor.Frontiers in veterinary science · 2023Article
- The Use of Oncept Melanoma Vaccine in Veterinary Patients: A Review of the Literature.Veterinary sciences · 2022Review
- Effects of Para-Toluenesulfonamide on Canine Melanoma Xenotransplants in a BALB/c Nude Mouse Model.Animals : an open access journal from MDPI · 2022Article
- Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.Journal for immunotherapy of cancer · 2022Article
- Treatment of Canine Oral Melanomas: A Critical Review of the Literature.Veterinary sciences · 2022Review
- Tumor-Associated Macrophages in Canine Oral and Cutaneous Melanomas and Melanocytomas: Phenotypic and Prognostic Assessment.Frontiers in veterinary science · 2022Article
- Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.Frontiers in veterinary science · 2022Article
- A Comparative View on Molecular Alterations and Potential Therapeutic Strategies for Canine Oral Melanoma.Veterinary sciences · 2021Review
- Diagnosis of meningeal melanomatosis in a dog using magnetic resonance imaging and cerebrospinal fluid findings.The Journal of veterinary medical science · 2021Article
- Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology).Frontiers in veterinary science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In dogs, melanomas are relatively common tumors and the most common form of oral malignancy. Biological behavior is highly variable, usually aggressive, and frequently metastatic, with reported survival times of three months for oral or mucosal melanomas in advanced disease stages. Classical clinical management remains challenging; thus, novel and more efficacious treatment strategies are needed. Evidence-based medicine supports the role of the immune system to treat neoplastic diseases. Besides, immunotherapy offers the possibility of a precise medicinal approach to treat cancer. In recent years, multiple immunotherapeutic strategies have been developed, and are now recognized as a pillar of treatment. In addition, dogs represent a good model for translational medicine purposes. This review will cover the most relevant immunotherapeutic strategies for the treatment of canine malignant melanoma, divided among five different categories, namely, monoclonal antibodies, nonspecific immunotherapy activated by bacteria, vaccines, gene therapy, and lymphokine-activated killer cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.